RADIKAL THERAPEUTICS, INC.
Biotech · Private
HSP70iQ435A (CM), a heat shock protein variant engineered to restore immune tolerance and arrest vitiligo depigmentation
- Grants
- $12M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 2 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Treatment of congenital heart disease associated pulmonary hypertension | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A pro-resolution lipid mediator for treatment of rheumatoid arthritis | $750,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · A pro resolution lipid mediator for treatment of rheumatoid arthritis | $1,500,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Restoration of free radical homeostasis novel therapy of septic shock | $2,443,579 | |
| Federal grant | Department of Health and Human Services · Phase II · Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | $1,468,688 | |
| Federal grant | Department of Health and Human Services · Phase II · Restoration of free radical homeostasis: novel therapy of septic shock | $1,194,948 | |
| Federal grant | Department of Health and Human Services · Phase II · A pro-resolution lipid mediator for treatment of rheumatoid arthritis | $750,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel immunotolerizing therapy for autoimmune vitiligo | $1,499,461 | |
| Federal grant | Department of Health and Human Services · Phase II · Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | $719,358 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel immunotolerizing therapy for autoimmune vitiligo | $460,375 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1621 | Verdiva Bio | — | — |
| 1622 | Furtim Therapeutics LLC | — | — |
| 1623 | NOVALEX THERAPEUTICS, INC. | — | — |
| 1624 | RADIKAL THERAPEUTICS, INC. | — | — |
| 1625 | Chan Zuckerberg Biohub | — | — |
| 1626 | ERADIVIR, INC. | — | — |
| 1627 | Sarkar-Klein-Labs | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Multifunctional Nitroxide Derivatives And Uses Thereofapplication
- Compositions And Methods For Treatment Of Inflammatory Diseases Of The Lungapplication
- Substituted 1-PYRROLIDINYLOXY, 1-PIPERIDINYLOXY And 1-AZEPANYLOXY Compounds For Treating Diseases Associated With Oxidative Stress Or Endothelial Dysfunctiongranted
- Multifunctional Nitroxide Derivatives And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.